The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Validation and revision of the RANO Leptomeningeal Metastasis Group scorecard for response assessment.
 
Emilie Le Rhun
Honoraria - Mundipharma; Novartis
Consulting or Advisory Role - Abbvie; Daiichi Sankyo
Research Funding - Amgen (Inst); Mundipharma (Inst)
 
Patrick Devos
No Relationships to Disclose
 
Thomas Boulanger
No Relationships to Disclose
 
Marion Smits
No Relationships to Disclose
 
Dieta Brandsma
No Relationships to Disclose
 
Roberta Ruda
Honoraria - Mundipharma; UCB
Consulting or Advisory Role - Mundipharma; UCB
 
Julia Furtner
No Relationships to Disclose
 
Johann-Martin Hempel
No Relationships to Disclose
 
Tjeerd Postma
No Relationships to Disclose
 
Patrick Roth
Honoraria - Novartis; Novocure
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Virometix
Research Funding - MSD (Inst)
 
Tom J. Snijders
No Relationships to Disclose
 
Frank Winkler
Research Funding - Boehringer Ingelheim (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Roche (Inst)
 
Sebastian Winklhofer
No Relationships to Disclose
 
Antonella Castellano
No Relationships to Disclose
 
Elke Hattingen
No Relationships to Disclose
 
Jaume Capellades
No Relationships to Disclose
 
Martin J. Van Den Bent
Consulting or Advisory Role - Abbvie; Agios; Bristol-Myers Squibb; Celgene; Celldex; Daiichi Sankyo; MSD
Research Funding - Abbvie (Inst)
 
Patrick Y. Wen
Consulting or Advisory Role - AbbVie; Agios; AstraZeneca; Deciphera; Genentech/Roche; GW Pharmaceuticals; Immunomic Therapeutics; KIYATEC; Lilly; Puma Biotechnology; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; ZIOPHARM Oncology
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Beigene (Inst); Genentech/Roche (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Vascular Biogenics (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
Martin Bendszus
Honoraria - B. Braun; Bayer; Boehringer Ingelheim; Codman; Guerbet; Novartis; Roche; Teva; Vascular Dynamics
Research Funding - Bayer (Inst); Codman (Inst); Deutsche Forschungsgemeinschaft (Inst); European Union (Inst); Federal Ministry of Education and Research (Inst); Guerbet (Inst); Hopp Foundation (Inst); Medtronic (Inst); Novartis (Inst); Siemens (Inst); Stryker (Inst)
 
Michael Weller
Honoraria - Merck Serono; MSD; Novocure; Roche
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Merck Serono; Orbus Therapeutics; Pfizer; Teva; Tocagen
Research Funding - Bayer (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novocure (Inst); OGD2 Pharma (Inst); Piqur (Inst); Roche (Inst); Tragara (Inst)